BRAF and neoplasm: BRAF: Although the presence of mutated BRAF, which is present in 5% to 10% of colon tumours, highlights the potential adverse prognostic factors for stage II and III disease and patients across all disease stages [90, 174], patients with BRAF-mutated tumours do not experience a survival benefit from treatment with anti-EGFR mAb.